Anti-cd30l antibodies and uses thereof
US-2024254246-A1 · Aug 1, 2024 · US
Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
US2016115236A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016115236-A1 |
| Application number | US-201514700521-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 30, 2015 |
| Priority date | Dec 28, 2006 |
| Publication date | Apr 28, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
First claim
Opening claim text (preview).
What is claimed is: 1 - 12 . (canceled) 13 . A pharmaceutical composition, comprising at least one agent that neutralizes CD95 activity to an individual with high grade glioma. 14 . The pharmaceutical composition of claim 13 , wherein the agent is Nok1 or APG101. 15 . A method for screening for an agent, which modulates/effects, preferably neutralizes the activity of CD95, comprising the steps (a) incubating a mixture comprising (i) CD95 or a functional fragment thereof (ii) a candidate agent under conditions whereby CD95 or a functional fragment thereof as a reference activity; (b) detecting the activity of CD95 or a functional fragment thereof to determine an activity in the presence of the agent; (c) determining a difference between the activity in the presence of the agent and the reference activity. 16 - 18 . (canceled)
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
of other specific parts of the body, e.g. brain · CPC title
comprising antibodies · CPC title
using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title
Detection of programmed cell death, i.e. apoptosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016115236A1 cover?
- The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
- Who is the assignee on this patent?
- Deutsches Krebsforsch, Universitaetsklinikum Heidelberg
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2875. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Apr 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).